Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27783636 | 0.83 | CNR1 (0.48) | CNR1KMT2AMEN1POLBLMNA | |
| SCHEMBL8790210 | 0.83 | MAPT (0.56) | KMT2AMEN1HTR2ALMNAMAPT | |
| Ammonia Solution, Strong SCHEMBL2522677 | 0.80 | CNR1 (0.41) | CNR1KMT2AMEN1POLBLMNA | |
| SCHEMBL2522674 | 0.78 | KMT2A (0.43) | CNR1KMT2AMEN1POLBLMNA | |
| SCHEMBL8351933 | 0.78 | CNR1 (0.45) | CNR1KMT2AMEN1POLBHTR2A | |
| SCHEMBL11607361 | 0.71 | ADRB2 (0.45) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2521895 | 0.70 | ALDH1A1 (0.53) | CNR1KMT2AMEN1POLBLMNA | |
| SCHEMBL11196790 | 0.70 | HTR2A (0.49) | CNR1KMT2AHTR2ALMNAMAPT | |
| SCHEMBL28305748 | 0.70 | ALDH1A1 (0.53) | CNR1KMT2AMEN1POLBLMNA | |
| SCHEMBL7093029 | 0.69 | TAAR1 (0.50) | HTR2ALMNAMAPTGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328091-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| CN-104876921-A | 5H-cyclopenta[d]pyrimidines As AKT Protein Kinase Inhibitors | ARRAY BIOPHARMA INC | 2015-09-02 | — | — | CN | disclosed |
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2250155-B1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8329709-B2 | 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| CN-101970415-A | 5H-cyclopenta [ d ] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2011-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | CNR1 3210/4885KMT2A 4172/4885MEN1 3499/4885 |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | CNR1 3210/4885KMT2A 4172/4885MEN1 3499/4885 |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | AKT3, PIK3CA, AKT2 | CNR1 3036/4885KMT2A 4150/4885MEN1 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.